- 2023.03.31
来佐利单抗 CD47
尤莱利单抗 CD73
TJ-CD4B Claudin 18.2 x 4-1BB
TJ-L14B PD-L1 x 4 -1BB
mRNA技术,隐蔽抗体技术
AI赋能研发,穿膜抗体技术
公司新闻稿
活动日历
Since its establishment, I-Mab has been focusing on developing innovative biologics in immuno-oncology. Through three waves of innovation, we have built a globally competitive pipeline. Our global clinical development and strategic partnership model fuels our sustainable innovation and growth, with proven track record of validation and recognition.
Jingwu Zang
Founder and Chairman